An observational study in Heart Failure, Heart Failure With Preserved Ejection Fraction (HFPEF) and Heart Failure With Reduced Ejection Fraction, sponsored by Satelia. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.
Sponsored by Satelia · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 448 studies in Heart Failure with a site in France — 90 open to participants now, 116 under way, 16 of them phase 3. Heart Failure · France.
Among the 448 studies in Heart Failure with a site in France, this one is the 10th largest by enrollment of the 161 observational ones that give a count, is one of 21 that started in 2021, is one of 161 observational ones, and was the 404th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →90 of the 448 studies in Heart Failure with a site in France are open now. Recruiting first, the newest first:
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
Poitiers University Hospital · Sites in France
Ages 18–90
University Hospital, Montpellier · Sites in France
Ages 18+
Oslo University Hospital · Sites in France, United States, Belgium and 7 more countries
Ages 18+
AstraZeneca · Sites in France, United States, Argentina and 29 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
448 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 28 · Phase 3 70 · Phase 4 15
First in 1983; this study’s year is marked. 21 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13,660 is above the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 196 across the 282 interventional studies, 321 across the 161 observational. Of the 290 that completed or were terminated, 74 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
184 of 448 have an industry lead sponsor. The 10 most frequent:
Satelia is the lead sponsor of 5 studies on the registry; none are open to participants now.
Satelia has 5 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
28 of the studies in Heart Failure with a site in France that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020263Phase 3Pr Bruno LEVYEffect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock | 2027-02-03 |
| NCT05879276Phase 3Central Hospital, Nancy, FranceEffect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. | 2027-03-16 |
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06518694Phase 3Assistance Publique - Hôpitaux de ParisBeta-blOckers discoNtinuation in Patients Presenting Heart FaIlure With REcovered Left Ventricular Ejection Fraction | 2027-10 |
Add all 28 to your calendar (.ics) → With an account.
Among the 448 studies in Heart Failure with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational cohort study evaluates temporal trends and determinants of sodium-glucose cotransporter 2 inhibitor (SGLT2i) prescriptions among adults with chronic heart failure enrolled in a nationwide remote monitoring program in France between 2021 and 2024. The analysis examines SGLT2i use at the time of enrollment in relation to left ventricular ejection fraction subgroups and evolving scientific evidence, including major clinical trial publications and guideline updates. Demographic, clinical, and healthcare setting factors associated with SGLT2i prescription in routine clinical practice are assessed using retrospective data from the remote monitoring program database. No study-mandated interventions were performed, and all treatments were prescribed as part of usual care.
This retrospective, multicenter observational cohort study was conducted in France between January 1, 2021 and December 31, 2024 within a nationwide heart failure (HF) remote monitoring program. The study included adult patients with chronic heart failure enrolled in the program following hospitalization for HF or in the ambulatory setting with elevated natriuretic peptide levels.
The remote monitoring program supports routine HF management using a digital platform that enables structured follow-up and communication between patients and healthcare providers. Clinical and treatment data recorded at the time of enrollment were extracted from the program database for analysis.
The primary objective of the study is to describe the prevalence of sodium-glucose cotransporter 2 inhibitor (SGLT2i) use at enrollment. Secondary objectives include evaluation of temporal trends in SGLT2i prescriptions across predefined time periods corresponding to major clinical trial publications and guideline updates, and identification of demographic, clinical, and healthcare setting factors associated with SGLT2i use.
Analyses focus on medication use as part of routine clinical care. No study-specific interventions were assigned, and all treatments were prescribed at the discretion of the treating clinicians. Statistical analyses include descriptive methods and multivariable regression modeling to assess factors independently associated with SGLT2i prescription.
The study population includes adults with chronic heart failure in France who were enrolled in a nationwide remote patient monitoring program between January 2021 and December 2024 as part of routine clinical care. Enrollment typically followed hospitalization for heart failure or occurred in ambulatory patients with elevated natriuretic peptide levels consistent with heart failure management guidelines. The cohort represents patients managed across a range of healthcare settings, including university hospitals, non-university hospitals, and outpatient practices.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Missing baseline medication data at the time of program enrolment
Adults with chronic heart failure enrolled in a nationwide remote patient monitoring program in France between January 2021 and December 2024. Clinical and treatment data at the time of enrollment were analyzed to evaluate patterns of sodium-glucose cotransporter 2 inhibitor use in routine care.
Other: SGLT2 Inhibitor Use
Prescription of a sodium-glucose cotransporter 2 inhibitor as part of routine clinical care at the time of enrollment in the remote monitoring program. Treatment decisions were made by the treating physician and were not study-mandated.
Prevalence of SGLT2 Inhibitor Use at Enrolment
Proportion of patients with chronic heart failure who were prescribed a sodium-glucose cotransporter 2 inhibitor as part of routine clinical care at the time of enrolment in the remote monitoring program.
Time frame: Prescription at time of enrolment into the remote monitoring program (baseline)
Temporal Trends in SGLT2 Inhibitor Use
Changes in the prevalence of SGLT2 inhibitor prescription over time according to study periods corresponding to major clinical trial publications and guideline updates.
Time frame: Across four predefined study periods between January 2021 and December 2024
Clinical and Healthcare Setting Factors Associated With SGLT2 Inhibitor Use
Association between demographic, clinical, and healthcare setting characteristics and likelihood of SGLT2 inhibitor prescription, assessed using multivariable regression analysis.
Time frame: At time of enrollment (baseline)
Plan to share: Undecided
Ran from Jan 2021 to primary completion in Dec 2024, 47 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.